We recently published our article 5 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market. To read the full article, head on to 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market. In this piece, we take a closer look at Structure Therapeutics Inc. (NASDAQ:GPCR) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Novo Nordisk A/S (NYSE: NVO) helped transform obesity treatment from a relatively overlooked pharmaceutical category into one of Wall Street’s biggest healthcare stories. The success of GLP-1 weight-loss drugs proved that effective obesity medicines could generate blockbuster sales, attract millions of patients and reshape how doctors treat metabolic disease.

The opportunity is enormous. Obesity affects hundreds of millions of people worldwide and is associated with type 2 diabetes, cardiovascular disease, fatty-liver disease, sleep apnea and other serious health conditions. Yet only a small percentage of eligible patients currently receives modern prescription weight-loss treatments. That gap explains why analysts believe the global weight-loss drug market could eventually exceed $100 billion in annual sales.

The Next Winners May Offer More Than Weight Loss

The next phase of the obesity drug boom will not be based solely on which treatment produces the highest percentage of weight loss. Drugmakers are now developing oral GLP-1 pills, monthly injections, dual- and triple-hormone therapies, amylin-based medicines and treatments designed to preserve muscle while patients lose fat.

Here is an important piece of trivia: weight loss does not come entirely from body fat. Patients may also lose lean tissue, including muscle, which has pushed biotechnology companies to develop complementary treatments that improve the quality of weight loss. Others are working on easier dosing, fewer gastrointestinal side effects and medicines that may also improve liver, heart and metabolic health.

Oral obesity treatments could become especially disruptive. Many patients dislike needles, while pills may be easier to manufacture, distribute and use. A successful weight-loss pill would not necessarily need to outperform every injectable treatment. Convenience alone could allow it to capture a meaningful portion of the growing obesity treatment market.

Why Biotech Stocks Are Entering the Spotlight

Novo Nordisk A/S (NYSE: NVO) remains the company framing this story, but it is not included in the top 10 ranking. Instead, the countdown focuses on biotechnology stocks attempting to benefit from the market Novo Nordisk helped create.

Some of these companies are developing direct competitors to existing GLP-1 drugs. Others are pursuing different mechanisms, longer-lasting treatments or therapies that could eventually be prescribed alongside popular weight-loss medicines. Their success could lead to major commercial partnerships, acquisition interest or sharp valuation increases.

The risks are equally significant. Obesity drug trials are expensive, clinical results can disappoint and smaller biotechnology companies may need additional financing before reaching commercialization. Investors searching for the best biotech stocks to buy now should therefore examine clinical progress, cash reserves, safety data, competitive advantages and upcoming catalysts—not just ambitious weight-loss claims.

The following countdown identifies 10 biotechnology stocks positioned to participate in the next stage of the $100 billion weight-loss drug market, beginning with number 10 and moving toward the company offering the strongest combination of scientific promise, market opportunity and investment potential.

CHECK THIS OUT: Top 10 AI-Powered Healthcare Stocks That Can Make You Rich and Top 10 Healthcare Stocks That Could Turn a $1000 Investment Into Something Bigger.

Our Methodology

In order to arrive to our list of the 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market, we examined the trending biotech stocks and based our ranking on each company’s clinical progress, treatment differentiation, market opportunity, financial position, upcoming catalysts, partnership potential and overall risk-reward profile within the rapidly growing obesity and metabolic-disease market.

5 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market

1. Structure Therapeutics Inc. (NASDAQ:GPCR)

For investors specifically seeking a smaller biotechnology stock with multibagger potential, Structure Therapeutics Inc. (NASDAQ: GPCR) earns the number one speculative position. This does not mean it is safer or fundamentally stronger than Eli Lilly and Company (NYSE: LLY) or Novo Nordisk A/S (NYSE: NVO). It means the company’s valuation could change more dramatically if aleniglipron successfully transitions from encouraging Phase 2 results into a registration-quality Phase 3 program.

The company has already shown placebo-adjusted weight loss above 16% at 44 weeks in ACCESS II, with continued reductions and no observed plateau. The published Phase 2b ACCESS findings give the program greater scientific credibility, while the planned Phase 3 start in the second half of 2026 creates a clear catalyst. Structure Therapeutics Inc. (NASDAQ: GPCR) is also developing an oral amylin program and combinations intended to strengthen its position beyond a single small-molecule GLP-1 product.

The upside case is simple: an effective, convenient and scalable oral medicine could capture a significant share of a market that may exceed $100 billion annually. The downside case is equally direct. Aleniglipron remains unapproved, its Phase 3 trials will be costly, and treatment discontinuations or unexpected safety findings could damage its commercial prospects. Novo Nordisk A/S (NYSE: NVO) and Eli Lilly and Company (NYSE: LLY) already have approved oral competitors, meaning Structure Therapeutics Inc. (NASDAQ: GPCR) must prove that its candidate is not merely effective but meaningfully competitive. For investors willing to accept clinical-stage risk, however, few independent obesity companies offer the same combination of advanced oral data and strategic scarcity.

YOU MUST READ THIS: 10 Biotech Stocks That Could Turn Medicine Into Wall Street’s Next Gold Rush

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.